The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

Lilly decided to hold off on the launch of the drug in GB until Mounjaro KwikPen was cleared for marketing. The drug has already been recommended for NHS use as a treatment for diabetes by cost ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

The company last year invested billions of dollars into its manufacturing capacity to ramp up Zepbound supplies and those of Mounjaro. Lilly last month said it expects $1.9 billion in Zepbound ...

Eli Lilly expects 2024 revenue to be $45 billion, with Mounjaro and Zepbound sales contributing significantly. The company aims to increase Zepbound’s market share, competing with Novo Nordisk ...